4//SEC Filing
McNeill Jonathan 4
Accession 0000950170-24-062075
CIK 0001818794other
Filed
May 16, 8:00 PM ET
Accepted
May 17, 9:03 PM ET
Size
7.3 KB
Accession
0000950170-24-062075
Insider Transaction Report
Form 4
McNeill Jonathan
See Remarks
Transactions
- Sale
Common Stock
2024-05-16$28.20/sh−2,279$64,268→ 137,129 total - Sale
Common Stock
2024-05-16$28.59/sh−495$14,152→ 136,634 total
Footnotes (4)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive.
- [F4]Includes 126,967 unvested RSUs.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001824673
Filing Metadata
- Form type
- 4
- Filed
- May 16, 8:00 PM ET
- Accepted
- May 17, 9:03 PM ET
- Size
- 7.3 KB